Intra-Cellular Therapies (Intra-Cellular Therapies) Interest Expense : $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Intra-Cellular Therapies Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Intra-Cellular Therapies's interest expense for the three months ended in Dec. 2023 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Intra-Cellular Therapies's Operating Income for the three months ended in Dec. 2023 was $ -34.1 Mil. Intra-Cellular Therapies's Interest Expense for the three months ended in Dec. 2023 was $ 0.0 Mil. GuruFocus does not calculate Intra-Cellular Therapies's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intra-Cellular Therapies Interest Expense Historical Data

The historical data trend for Intra-Cellular Therapies's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Interest Expense Chart

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

Intra-Cellular Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Intra-Cellular Therapies Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Intra-Cellular Therapies (NAS:ITCI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intra-Cellular Therapies's Interest Expense for the three months ended in Dec. 2023 was $0.0 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-34.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $13.3 Mil.

Intra-Cellular Therapies's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate Intra-Cellular Therapies's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Intra-Cellular Therapies Inc has enough cash to cover all of its debt. Its financial situation is stable.

Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ITCI:Mexico 23I:Germany 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Executives

Sharon Mates	director, officer: Chairman, President & CEO	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead	officer: SVP and General Counsel	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Suresh K. Durgam	officer: Chief Medical Officer	C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Mark Neumann	officer: EVP, Chief Commercial Officer	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline	officer: VP of Finance, CFO & Secretary	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas	director	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs	director	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Christopher D Alafi	director, 10 percent owner	P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner	director	THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin	officer: EVP and Chief Medical Officer	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover	officer: VP, Clinical Development	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis	officer: SVP, Chief Scientific Officer	3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi	10 percent owner	1311 ORLEANS DRIVE, SUNNYVALE CA 94089